Microscopic Lassa virus particle morphing into a shield, protecting a diverse West African community.

Lassa Virus: Can We Outsmart This Biothreat?

Author's portrait.
Rhea Morgan in Health & Wellness December 2025 • 4 min read.

"Exploring innovative approaches to broaden our immune response and develop effective vaccines against Lassa fever."


In 2017, the global Coalition for Epidemic Preparedness (CEPI) identified Lassa virus disease as a top-priority biothreat, and in January 2018, the World Health Organization (WHO) convened experts to address this pressing issue. What makes Lassa virus so challenging is its extensive diversity; the genetic variation among Lassa virus isolates from West African patients surpasses that of Ebola virus during the 2013-2016 epidemic.

This genetic variability creates a significant hurdle for vaccine development, demanding that vaccines offer broad protection against a wide range of Lassa virus strains. Researchers are actively exploring how to stimulate the immune system to recognize and defend against these diverse viral threats.

This article examines the current understanding of the immune response to Lassa virus infection and discusses strategies for designing broadly protective vaccines. We'll explore approaches used in influenza vaccine development and recent advances in AIDS research, considering their potential application in creating effective medical countermeasures against Lassa virus disease.

Why is Lassa Virus So Hard to Target?

Microscopic Lassa virus particle morphing into a shield, protecting a diverse West African community.

Lassa virus (LASV) is a zoonotic pathogen that's endemic to West Africa, causing annual outbreaks primarily during the dry season in rural areas. Unlike the concentrated outbreaks of Ebola, Lassa outbreaks stem from varied exposures to the rodent reservoir, leading to its high genetic variation. This means any effective vaccine needs to cover a broader range of viral strains than, for example, an Ebola vaccine.

The virus also impacts the body by affecting dendritic cell function, which results in poor antigen-presentation and immunosuppression, which allows unchecked replication [10-12]. In both monkeys and humans, neutralizing antibodies develop slowly, in part because glycans on the viral envelope (GP) mimic self-glycans, essentially camouflaging the virus from the immune system [13].

  • Vaccine Cross-Protection: Reflects the genetic diversity a vaccine can handle.
  • Narrow Protection: Only effective against closely-related Lassa lineages (5-7% nucleotide sequence difference).
  • Broad Protection: Could defend against all Lassa lineages (up to 27% nucleotide difference).
  • Ideal Scenario: Protection against other arenavirus species (30-50% nucleotide difference, e.g., between LASV and LCMV).
Despite the challenges, researchers are making strides. Several Lassa virus vaccine candidates have shown promise in animal models, particularly a live attenuated MOP/LAS reassortant vaccine (ML29). This vaccine has demonstrated sterilizing protection in mice, guinea pigs, and non-human primates, eliciting immune responses to both LASV glycoprotein (GP) and nucleoprotein (NP), even in primates with SIV [14-18].

The Future of Lassa Fever Protection

While current research offers hope, there's a need for more comprehensive comparisons of existing vaccine candidates. Factors like stability, production capacity, and the breadth of protection in primates remain unknown. Once these are established, efforts should focus on two key areas: developing affordable vaccines for emergency use in endemic regions and creating more specialized vaccines for vulnerable populations like pregnant women.

Further improvements in vaccine design should aim to boost immunity to conformational antigens—those that maintain stable functionality during virus evolution. Also, targeting epitopes known to tightly bind to HLA (human leukocyte antigen) and cross-restrict with conformational antigens could yield more broadly effective immune responses.

By combining these advanced vaccine strategies with effective therapeutic drugs, we can significantly improve our ability to combat Lassa fever and protect vulnerable communities.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.3390/pathogens7040084, Alternate LINK

Title: Improving The Breadth Of The Host’S Immune Response To Lassa Virus

Subject: Infectious Diseases

Journal: Pathogens

Publisher: MDPI AG

Authors: Juan Zapata, Sandra Medina-Moreno, Camila Guzmán-Cardozo, Maria Salvato

Published: 2018-10-28

Everything You Need To Know

1

Why is it so difficult to develop a vaccine against Lassa fever?

Lassa fever is a significant global health concern, primarily due to the Lassa virus's extensive genetic diversity. This variability means that vaccines must offer broad protection against a wide range of Lassa virus strains to be effective. This genetic diversity is a major hurdle in vaccine development, making it more difficult to create a single vaccine that can protect against all strains of the Lassa virus.

2

How does genetic diversity of Lassa virus affect vaccine development?

The genetic diversity of the Lassa virus is a major challenge because it leads to varied exposure to the rodent reservoir, which causes outbreaks. Vaccine Cross-Protection, the ability of a vaccine to handle genetic diversity, is crucial. Narrow Protection only covers closely-related Lassa lineages, while Broad Protection defends against a wider range of strains. The goal is to achieve Broad Protection to effectively combat the virus.

3

What approaches are being used to develop a Lassa virus vaccine?

Researchers are exploring strategies to stimulate the immune system to recognize and defend against various Lassa virus strains. Approaches used in influenza vaccine development and recent advances in AIDS research are being considered. A live attenuated MOP/LAS reassortant vaccine (ML29) has shown promise in animal models by eliciting immune responses to both LASV glycoprotein (GP) and nucleoprotein (NP).

4

How does the Lassa virus evade the immune system?

The Lassa virus impacts the body by affecting dendritic cell function, resulting in poor antigen-presentation and immunosuppression. The virus uses glycans on the viral envelope (GP) to mimic self-glycans, which camouflages it from the immune system, thereby slowing the development of neutralizing antibodies. Addressing these mechanisms is crucial for developing effective vaccines.

5

What are the next steps in Lassa fever protection?

Current research offers hope, but there's a need for more comprehensive comparisons of existing vaccine candidates. Key factors like stability, production capacity, and the breadth of protection in primates remain unknown. Future efforts should focus on developing affordable vaccines for emergency use in endemic regions and creating more specialized vaccines for vulnerable populations like pregnant women. This will improve the chances of protecting those most at risk.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.